RP-A601
RP-A601-0323
Phase 1 gene_therapy active
Quick answer
RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) is a Phase 1 program (gene_therapy) at Rocket Pharmaceuticals B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Rocket Pharmaceuticals B.V.
- Indication
- PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
- Phase
- Phase 1
- Modality
- gene_therapy
- Status
- active